- Home
- ANET vs AZN Comparison
ANET vs AZN Comparison
Compare ANET & AZN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ANET | AZN |
|---|---|---|
| Founded | 2004 | 1992 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Computer Communications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 238.0B | 250.7B |
| IPO Year | 2014 | 1995 |
Fundamental Metrics
Financial Performance| Metric | ANET | AZN |
|---|---|---|
| Price | $216.48 | $159.46 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 32 | 12 |
| Target Price | ★ $243.69 | $206.91 |
| AVG Volume (30 Days) | ★ 4.3M | 2.4M |
| Earning Date | 11-03-2026 | 10-30-2026 |
| Dividend Yield | N/A | ★ 2.03% |
| EPS Growth | ★ 23.32 | N/A |
| EPS | ★ 1.75 | N/A |
| Revenue | ★ $9,005,700,000.00 | N/A |
| Revenue This Year | $40.80 | $7.52 |
| Revenue Next Year | $28.89 | $6.16 |
| P/E Ratio | $120.55 | ★ $31.91 |
| Revenue Growth | ★ 28.60 | N/A |
| 52 Week Low | $114.52 | $80.48 |
| 52 Week High | $217.32 | $212.71 |
Technical Indicators
Market Signals| Indicator | ANET | AZN |
|---|---|---|
| Relative Strength Index (RSI) | 63.76 | 44.42 |
| Support Level | $183.40 | $154.89 |
| Resistance Level | N/A | $169.77 |
| Average True Range (ATR) | 5.61 | 2.79 |
| MACD | 0.80 | -0.43 |
| Stochastic Oscillator | 96.14 | 31.09 |
Price Performance
Historical ComparisonAbout ANET Arista Networks Inc.
Arista Networks is a networking equipment provider that primarily sells Ethernet switches and software to data centers. Its marquee product is its extensible operating system that runs a single image across every single one of its devices. The firm operates as one reportable segment. It has steadily gained market share since its founding in 2004, with a focus on high-speed applications. Arista counts Microsoft and Meta Platforms as its largest customers and derives roughly three-fourths of its sales from North America.
About AZN AstraZeneca PLC
A merger between Astra of Sweden and Zeneca of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (over 40% of total revenue), cardiovascular, renal, and metabolic (over 20%), rare disease (16%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one-third of its sales.